Wedbush Reduces Earnings Estimates for Spyre Therapeutics

Spyre Therapeutics, Inc. (NASDAQ:SYRE) – Investment analysts at Wedbush decreased their Q1 2025 earnings per share estimates for shares of Spyre Therapeutics in a research report issued on Tuesday, November 12th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings of ($0.86) per share for the quarter, down from their prior estimate of ($0.84). Wedbush has a “Outperform” rating and a $45.00 price target on the stock. The consensus estimate for Spyre Therapeutics’ current full-year earnings is ($4.89) per share. Wedbush also issued estimates for Spyre Therapeutics’ Q2 2025 earnings at ($0.78) EPS, Q3 2025 earnings at ($0.75) EPS, Q4 2025 earnings at ($0.76) EPS, FY2025 earnings at ($3.15) EPS, FY2026 earnings at ($2.83) EPS, FY2027 earnings at ($2.82) EPS and FY2028 earnings at ($2.98) EPS.

Several other research analysts also recently commented on SYRE. Robert W. Baird increased their price objective on shares of Spyre Therapeutics from $50.00 to $65.00 and gave the company an “outperform” rating in a report on Wednesday. Guggenheim increased their target price on Spyre Therapeutics from $50.00 to $65.00 and gave the company a “buy” rating in a research report on Friday, October 25th. Ten research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $48.57.

Spyre Therapeutics Stock Performance

SYRE stock opened at $29.20 on Friday. The company’s fifty day moving average price is $31.34 and its 200-day moving average price is $30.39. Spyre Therapeutics has a one year low of $8.75 and a one year high of $47.97. The company has a market capitalization of $1.50 billion, a PE ratio of -3.91 and a beta of 2.90.

Hedge Funds Weigh In On Spyre Therapeutics

Several hedge funds have recently bought and sold shares of SYRE. SG Americas Securities LLC bought a new stake in shares of Spyre Therapeutics during the second quarter worth $130,000. EFG Asset Management North America Corp. bought a new stake in Spyre Therapeutics during the 2nd quarter valued at about $869,000. Bank of New York Mellon Corp purchased a new stake in Spyre Therapeutics in the 2nd quarter valued at about $2,767,000. Rhumbline Advisers purchased a new stake in Spyre Therapeutics in the 2nd quarter valued at about $1,220,000. Finally, TD Asset Management Inc bought a new position in Spyre Therapeutics in the 2nd quarter worth about $827,000. Institutional investors own 80.39% of the company’s stock.

Spyre Therapeutics Company Profile

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).